Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.
Wei LiuHesong ZouLianting ChenWenyang HuangRui LvYan XuHuimin LiuYin ShiKefei WangYi WangWenjie XiongShuhui DengShuhua YiWeiwei SuiGuangxin PengYueshen MaHuijun WangLulu LvJian-Xiang WangJun WeiLugui QiuWenting ZhengDehui ZouPublished in: Journal for immunotherapy of cancer (2024)
ChiCTR1900025419 and NCT04690192.